Program
Oxycodone
Also written as “Reformulated OXY (oxycodone HCl)”, “Oxycodone/Naloxone” and “oxycodone hydrochloride”.
Its studies are mostly in Pain · Neoplasms · Osteoarthritis · Cancer Pain · Chronic Pain, led by 13 companies.
Drug pageOxycodone: every studyMany companies study it; this page follows only the 64 they lead. All 209 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mundipharmaits history only | 200 open or running | phase 4since Mar 8, 2011 | Jul 27, 2007 | none ahead |
| Knoa Pharmaits history only | 120 open or running | phase 3since Apr 6, 2006 | Apr 6, 2006 | none ahead |
| Pain Therapeuticsits history only | 120 open or running | phase 3since Mar 13, 2012 | Aug 12, 2008 | none ahead |
| Pfizerits history only | 60 open or running | phase 4since Jun 8, 2007 | Jun 8, 2007 | none ahead |
| Egaletits history only | 30 open or running | phase 3since Nov 10, 2015 | Dec 2, 2008 | none ahead |
| Keenova Therapeuticsits history only | 30 open or running | phase 1since Feb 26, 2009 | Feb 26, 2009 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| biodelivery-sciences-internationalits history only | 10 open or running | phase 1since Jun 21, 2019 | Jun 21, 2019 | none ahead |
| elite-laboratories-incits history only | 10 open or running | phase 3since Feb 17, 2015 | Feb 17, 2015 | none ahead |
| gl-pharm-tech-corporationits history only | 10 open or running | phase 1since Mar 19, 2012 | Mar 19, 2012 | none ahead |
| Indivior Pharmaceuticals | 10 open or running | phase 1since Nov 16, 2018 | Nov 16, 2018 | none ahead |
| napp-pharmaceuticals-limitedits history only | 10 open or running | phase 4since Nov 3, 2008 | Nov 3, 2008 | none ahead |
| vistapharm-incits history only | 10 open or running | phase 4since Jul 3, 2013 | Jul 3, 2013 | none ahead |
Also a collaborator on its studies: PRA Health Sciences and Grünenthal.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Indivior Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 16, 2018First study: phase 1 study in HealthyFirst studyNCT03747341 · 22 enrolled · Netherlands
TargetBeta
“Mu opioid receptor agonist; Mu opioid receptor agonist; Mu opioid receptor agonist”ChEMBL 37, by rule
Other programs on OPRM1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 20 |
| Methadonerule | Merck | phase 4 | 16 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
| axelopranrule | glycyx-therapeutics | phase 2 | 8 |
| Alfentanilrule | Sichuan Kelun Pharmaceutical | phase 1 | 1 |
Studies
The one study Indivior Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03747341Healthy · Netherlands | 1 | Completed | Jan 4, 2019 | 22 |
How it is read
Names in the registry
- “Oxycodone”, 43 entries
- “Reformulated OXY (oxycodone HCl)”, 6 entries
- “Oxycodone/Naloxone”, 5 entries
- “oxycodone hydrochloride”, 4 entries
- “Oxycodone hydrochloride”, 3 entries
Conditions, from the studies’ own filings
- Pain, 15 studies
- Neoplasms, 7 studies
- Osteoarthritis, 4 studies
- Cancer Pain, 3 studies
- Chronic Pain, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.